Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002444667 | SCV002753841 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-04-29 | criteria provided, single submitter | clinical testing | The p.G1023R variant (also known as c.3067G>A), located in coding exon 19 of the ATM gene, results from a G to A substitution at nucleotide position 3067. The glycine at codon 1023 is replaced by arginine, an amino acid with dissimilar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV000161935 | SCV000211920 | uncertain significance | Ataxia-telangiectasia syndrome | 2015-02-18 | no assertion criteria provided | clinical testing | |
Natera, |
RCV000161935 | SCV002079060 | uncertain significance | Ataxia-telangiectasia syndrome | 2020-12-15 | no assertion criteria provided | clinical testing |